Loading…

Radiotherapy for hormone-sensitive prostate cancer with synchronous low burden of distant metastases

Purpose The DEGRO Expert Commission on Prostate Cancer has revised the indication for radiation therapy of the primary prostate tumor in patients with synchronous distant metastases with low metastatic burden. Methods The current literature in the PubMed database was reviewed regarding randomized ev...

Full description

Saved in:
Bibliographic Details
Published in:Strahlentherapie und Onkologie 2022-08, Vol.198 (8), p.683-689
Main Authors: Müller, Arndt-Christian, Aebersold, Daniel M., Albrecht, Clemens, Böhmer, Dirk, Flentje, Michael, Ganswindt, Ute, Ghadjar, Pirus, Schmidt-Hegemann, Nina-Sophie, Höcht, Stefan, Hölscher, Tobias, Niehoff, Peter, Pinkawa, Michael, Sedlmayer, Felix, Wolf, Frank, Zamboglou, Constantinos, Zips, Daniel, Wiegel, Thomas
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose The DEGRO Expert Commission on Prostate Cancer has revised the indication for radiation therapy of the primary prostate tumor in patients with synchronous distant metastases with low metastatic burden. Methods The current literature in the PubMed database was reviewed regarding randomized evidence on radiotherapy of the primary prostate tumor with synchronous low metastatic burden. Results In total, two randomized trials were identified. The larger study, the STAMPEDE trial, demonstrated an absolute survival benefit of 8% after 3 years for patients with low metastatic burden treated with standard of care (SOC) and additional radiotherapy (RT) (EQD2 ≤ 72 Gy) of the primary tumor. Differences in the smaller Horrad trial were not statistically significant, although risk reduction in the subgroup (
ISSN:0179-7158
1439-099X
DOI:10.1007/s00066-022-01961-y